Concizumab may be effective prophylaxis for hemophilia A or B with inhibitors

Sufferers with hemophilia A or B with inhibitors have a decrease annualized bleeding price with concizumab than with no prophylaxis, in line with a part 3 research printed on-line Aug. 31 within the New England Journal of Medication.

Tadashi Matsushita, M.D., Ph.D., from Nagoya College Hospital in Japan, and colleagues evaluated the protection and efficacy of concizumab in patients with hemophilia A or B with inhibitors. As a part of the explorer7 part 3 trial, contributors have been randomly assigned to obtain no prophylaxis for a minimum of 24 weeks (group 1; 19 sufferers) or to obtain concizumab prophylaxis for a minimum of 32 weeks (group 2; 33 sufferers), or they have been nonrandomly assigned to obtain concizumab prophylaxis for a minimum of 24 weeks (teams 3 and 4; 81 sufferers).

The researchers discovered that the estimated imply annualized bleeding price in group 1 was 11.8 episodes versus 1.7 episodes in group 2 (price ratio, 0.14; P < 0.001). For sufferers receiving concizumab (teams 2, 3, and 4), the general median annualized bleeding price was zero episodes. After concizumab remedy was restarted, no thromboembolic occasions have been reported. Plasma concentrations of concizumab have been steady over time.

“Concizumab represents a novel, subcutaneous therapy possibility in sufferers with hemophilia A or B with inhibitors that may probably enhance long-term outcomes,” the authors write.

Copyright © 2023 HealthDay. All rights reserved.